Company Filing History:
Years Active: 2010
Title: Innovations of Yongbo Hu in Peptide Inhibitors
Introduction
Yongbo Hu is an accomplished inventor based in Lawrence, Kansas, known for his significant contributions to the field of peptide inhibitors. His innovative work focuses on developing novel peptide sequences that have the potential to impact immune response modulation.
Latest Patents
Yongbo Hu holds a patent for "Signal-1/signal-2 bifunctional peptide inhibitors." This patent describes a unique peptide sequence characterized by the general formula AB, where A and B represent chains of amino acid residues. The A chain is designed to bind with a major histocompatibility complex on an antigen-presenting cell, while the B chain binds with a Signal-2 receptor on the same cell. The invention also includes preferred forms of the peptide sequence that feature an X chain positioned between the A and B chains. Notably, the A chain exhibits at least 10% sequence homology with a Signal-1 moiety, and the B chain shows similar homology with a Signal-2 receptor moiety. This innovative peptide sequence is capable of shifting immune responses, which could have significant therapeutic implications.
Career Highlights
Yongbo Hu is affiliated with the University of Kansas Medical Center Research Institute, where he conducts his research and development work. His career is marked by a commitment to advancing the understanding of immune responses through innovative peptide design.
Collaborations
Yongbo Hu collaborates with esteemed colleagues, including Joseph S. Murray and Teruna J. Siahaan, who contribute to his research endeavors and enhance the impact of his work.
Conclusion
Yongbo Hu's innovative contributions to peptide inhibitors represent a significant advancement in the field of immunology. His patented work has the potential to influence future therapeutic strategies for immune response modulation.